Offer - Urjas Oil for just ₹ 1 X
Mirbeg-S 25 Tablet ER is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Mirbeg-S 25 Tablet ER safe for pregnant women?
Mirbeg S 25 Tablet can have harmful effects in pregnant women. If you experience any discomfort after using Mirbeg S 25 Tablet, then discontinue the use and take your doctor's advice.
Is the use of Mirbeg-S 25 Tablet ER safe during breastfeeding?
Mirbeg S 25 Tablet may lead to some side effects in breastfeeding women. If you witness any unusal symptoms after taking Mirbeg S 25 Tablet, discontinue its use and call your doctor right away. Follow your doctor's advice regarding the use of Mirbeg S 25 Tablet.
What is the effect of Mirbeg-S 25 Tablet ER on the Kidneys?
Very few cases of side effects of Mirbeg S 25 Tablet on kidney have been reported.
What is the effect of Mirbeg-S 25 Tablet ER on the Liver?
Mirbeg S 25 Tablet has very mild side effects on the liver.
What is the effect of Mirbeg-S 25 Tablet ER on the Heart?
Mirbeg S 25 Tablet has very mild side effects on the heart.
If you are suffering from any of the following diseases, you should not take Mirbeg-S 25 Tablet ER unless your doctor advises you to do so -
Is this Mirbeg-S 25 Tablet ER habit forming or addictive?
No, you will not get addicted to Mirbeg-S 25 Tablet ER.
Interaction between Food and Mirbeg-S 25 Tablet ER
You can take Mirbeg-S 25 Tablet ER with food.
Interaction between Alcohol and Mirbeg-S 25 Tablet ER
Taking alcohol with Mirbeg-S 25 Tablet ER can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 864
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Myrbetriq (mirabegron)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Betmiga® (mirabegron)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; VESIcare® (solifenacin succinate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1151